Boehringer Ingelheim

Release Summary

Boehringer Ingelheim today announced a new post-hoc subanalysis of the WISDOM study suggesting only 4 out of 100 people with COPD may benefit from ICS on top of tiotropium Respimat®

Boehringer Ingelheim